Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 9/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831645 | 1.00 | CYP17A1 (0.35) | CYP17A1EGFRTRPA1CYP1A2CYP3A4 | |
| SCHEMBL3308499 | 0.80 | EGFR (0.35) | EGFRKDR | |
| SCHEMBL5930649 | 0.80 | EGFR (0.39) | CYP17A1EGFRCYP1A2CYP3A4TSHR | |
| SCHEMBL31143775 | 0.80 | EGFR (0.35) | EGFRKDR | |
| SCHEMBL3262187 | 0.80 | MEN1 (0.35) | EGFRCSNK2A2CSNK2BCSNK2A1MAP4K4 | |
| SCHEMBL25215782 | 0.76 | EGFR (0.37) | EGFR | |
| SCHEMBL4036487 | 0.71 | EGFR (0.47) | EGFRMAP4K4 | |
| SCHEMBL31378742 | 0.69 | MAP4K4 (0.32) | EGFRMAP4K4 | |
| SCHEMBL22326646 | 0.69 | CYP1A2 (0.38) | CYP1A2 | |
| SCHEMBL22326645 | 0.69 | TET2 (0.38) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110248935-A | For treating the nitrogenous bicyclic derivatives of pain and pain associated disorder | 埃斯特韦制药股份公司 | 2019-09-17 | — | — | CN | disclosed |
| EP-1871769-B1 | CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE. | ASTRAZENECA AB (SE) | 2017-02-22 | — | — | EP | disclosed |
| CN-105916506-A | Quinazoline derivatives as inhibitors of TAM family kinases | 圣诺康生命科学公司 | 2016-08-31 | — | — | CN | disclosed |
| US-8304417-B2 | Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline | ASTRAZENECA AB (SE) | 2012-11-06 | — | — | US | disclosed |
| US-20090099196-A1 | Chemical Process | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099196-A1 | Chemical Process | CYP3A5, CYP3A43, CYP3A7 | CYP17A1 2027/4885EGFR 2358/4885TRPA1 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.